Borrás-Blasco Joaquín, Gracia-Perez Antonio, Rosique-Robles J Dolores, Nuñez-Cornejo Claudia, Casterá M D Elvira, Abad F Javier
Pharmacy Service and Rehabilitation Section, Hospital de Sagunto, Sagunto, Spain.
South Med J. 2009 Mar;102(3):304-5. doi: 10.1097/SMJ.0b013e31819450e7.
A 50-year-old woman was referred to our emergency room because of urticaria. Eleven days after etanercept therapy was started, the patient developed an urticarial rash of the trunk and face. A diagnosis of generalized urticaria was made. Etanercept treatment was suspended. Treatment was started with methylprednisolone and dexchlorpheniramine. The patient's condition improved and she was discharged. In this case, the most probable cause of urticaria was considered to be etanercept because of the temporal relationship between exposure to the drug and the onset of symptoms. The adverse reaction could be considered probable. Although the overall risk of skin adverse events associated with etanercept appears low, clinicians should be aware of this reaction.
一名50岁女性因荨麻疹被转诊至我们的急诊室。在开始使用依那西普治疗11天后，患者出现了躯干和面部的荨麻疹皮疹。诊断为全身性荨麻疹。依那西普治疗被暂停。开始使用甲泼尼龙和右氯苯那敏进行治疗。患者病情好转并出院。在该病例中，由于接触药物与症状发作之间的时间关系，荨麻疹最可能的原因被认为是依那西普。该不良反应可被认为是很可能发生的。尽管与依那西普相关的皮肤不良事件的总体风险似乎较低，但临床医生应意识到这种反应。
